Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 10 April 2018

Indication(s)

Mycophenolate mofetil Teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Load more

Related Content

Journal articles

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.

Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons...

Added 1 month ago

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients

Venous thromboembolism (VTE) is a potential cause of morbidity and mortality in patients after major orthopaedic surgery. Based on the...

Added 2 years ago

Dexmedetomidine Based Sedation for Post-surgery Critically Ill Adults: A Meta-analysis of Randomized Controlled Trials.

Using dexmedetomidine (Dex) as a sedative agent may benefit the clinical outcomes of post-surgery patients. We reviewed randomized controlled trials to assess whether use of a Dex could improve the outcomes in post-surgery critically ill adults.

Added 2 months ago

Clinical predictors and risk factors for vaginal mesh extrusion.

Our study aims to enhance the accuracy of the clinical diagnosis in patients with vaginal mesh extrusion following transvaginal mesh placement for pelvic organ prolapse using significant clinical parameters and risk factors.

Added 3 months ago

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

Background: Adherence to oral anticoagulant (OAC) agents is important for patients with nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events.

Added 6 months ago

Load more

View all 12628 Journal articles items
Guidelines

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management

These Guidelines are intended for physicians and collaborators involved in the pre-operative, operative, and post-operative care of patients undergoing non-cardiac surgery.

Added 3 years ago

Guideline on aspects of cancer-related venous thrombosis

This guideline reviews the indication for warfarin, duration or treatment for patients with a PE and/or lower limb DVT, the initiation of treatment, the management of peri-operative anticoagulation, the management of patients who are bleeding or...

Added 2 years ago

Management of cytomegalovirus infection in haemopoietic stem cell transplantation

These evidence-based guidelines expand and adapt previous guidance (Tomblyn et al, 2009; Andrews et al, 2011). While specifically focusing on...

Added 4 years ago

Load more

View all 1437 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/000882
Orphan designation No
Date First Approved 21-02-2008
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Teva Pharma B.V.